You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | -326.3% | -133.6% |
ROCE | 0.0% |
Latest | Forecast | |
---|---|---|
P/E | -3.2 | 0.0 |
PEG | 0.0 | -999,999.0 |
Price / Revenue | 17.8 | 7.2 |
Price / Book value | 9.3 |
Latest | Forecast | |
---|---|---|
Revenue | 228.2% | 8.3% |
PBT | 0.0% | n/a |
EPS | 0.0% | 31.5% |
DPS | n/a | 0.0% |
Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2019-12-31 | 5.51 | -18.05 | -12.98p | -1.3 | 0.0 | n/a | n/a | 0.0% |
2020-12-31 | 2.14 | -18.86 | -7.27p | -15.7 | 0.0 | n/a | n/a | 0.0% |
2021-12-31 | 2.94 | -29.19 | -10.57p | -12.0 | 0.0 | n/a | n/a | 0.0% |
2022-12-31 | 9.65 | -41.46 | -15.48p | -7.4 | 0.0 | n/a | n/a | 0.0% |
Avacta reaches milestone in AVA6000 dose escalation Sharecast News | 21 Mar |
---|---|
Avacta tumbles after raising £25.7m in heavily discounted placing Sharecast News | 29 Feb |
Avacta appoints new head of research and development Sharecast News | 19 Jan |
Update on AVA6000 Phase 1a Clinical Trial Progress | 21-Mar-24 09:14 |
---|---|
Result of General Meeting | 18-Mar-24 13:27 |
Avacta Announces AVA6000 Poster at AACR | 06-Mar-24 09:32 |
Result of REX Retail Offer | 05-Mar-24 07:01 |
Result of Placing | 29-Feb-24 07:01 |